1. Home
  2. MFIC vs XERS Comparison

MFIC vs XERS Comparison

Compare MFIC & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MidCap Financial Investment Corporation

MFIC

MidCap Financial Investment Corporation

HOLD

Current Price

$11.02

Market Cap

1.0B

Sector

Finance

ML Signal

HOLD

XERS

Xeris Biopharma Holdings Inc.

HOLD

Current Price

$6.27

Market Cap

1.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MFIC
XERS
Founded
2004
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
1.0B
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
MFIC
XERS
Price
$11.02
$6.27
Analyst Decision
Hold
Buy
Analyst Count
7
6
Target Price
$11.25
$10.83
AVG Volume (30 Days)
616.8K
1.6M
Earning Date
05-06-2026
05-07-2026
Dividend Yield
10.84%
N/A
EPS Growth
N/A
100.00
EPS
N/A
0.01
Revenue
N/A
$49,590,000.00
Revenue This Year
N/A
$34.37
Revenue Next Year
N/A
$22.86
P/E Ratio
$10.50
$636.50
Revenue Growth
N/A
142.67
52 Week Low
$9.48
$4.30
52 Week High
$13.51
$10.08

Technical Indicators

Market Signals
Indicator
MFIC
XERS
Relative Strength Index (RSI) 39.20 51.90
Support Level $10.92 $6.26
Resistance Level $11.81 $6.41
Average True Range (ATR) 0.30 0.28
MACD -0.12 0.00
Stochastic Oscillator 8.82 28.50

Price Performance

Historical Comparison
MFIC
XERS

About MFIC MidCap Financial Investment Corporation

MidCap Financial Investment Corp is an externally managed, publicly traded, closed-end, diversified management investment company. Its investment objective is to generate current income and, to a lesser extent, long-term capital appreciation. It predominantly invests in directly originated and privately negotiated first lien senior secured loans to privately held U.S. middle-market companies, and in other types of securities including, first lien unitranche, second lien senior secured, unsecured, subordinated, and mezzanine loans, and equities in both private and public middle market companies.

About XERS Xeris Biopharma Holdings Inc.

Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.

Share on Social Networks: